HPV is the most common sexually transmitted infection in the US, resulting in cancers of the anus, head and neck/oropharyngeal route, and penis in men. Although the HPV vaccine can prevent up to 90% of all HPV- associated cancers, vaccination rates among males remain significantly lower than those of females. Hispanic men tend to delay seeking preventive health services or help-seeking behavior which has been attributed to the role of masculinity and possibly access to care, creating missed opportunities for cancer prevention, early cancer screening, and diagnosis. The delay in screening and diagnosis can prolong treatment and alter the prognosis of indolent HPV- associated cancers. In order to begin to understand the complexities associated with screening the state of the science, the proposal has outlined the following three specific aims: (a) assess changes in HPV-associated cancer diagnoses* in Hispanic men, since the HPV vaccine became available (first recommended in 2006); (b) determine if acculturation, place of residence (rural vs. urban, border county, e.g.), and/or having a primary care provider have an impact on being diagnosed with HPV-related cancers* at an earlier stage; (c) identify differences in HPV-associated cancer diagnoses* through diagnostic and screening practices in Hispanic men with symptoms (e.g., anogenital warts, intraepithelial neoplasia, carcinoma mass) than those who don't report symptoms. To address the aforementioned aims, the proposed pilot grant will support a comparative effectiveness (CER) approach to explore big data sources from the Texas Cancer Registry and the state-based Centers for Medicare & Medicaid Services (CMS) to further understand the associated HPV-cancer-related disparities in Hispanic men.